



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Ke-Wei Sun,
keweisun550@163.com

[†]These authors have contributed equally
to this work

SPECIALTY SECTION
This article was submitted to
Experimental Pharmacology
and Drug Discovery,
a section of the journal
Frontiers in Pharmacology

RECEIVED 23 November 2022
ACCEPTED 24 November 2022
PUBLISHED 01 December 2022

CITATION
Tang D, Wang R-Y, Sun K-W, Wu Y,
Ding L and Mo Y (2022), Corrigendum:
Network pharmacology-based
prediction of active compounds in
Wenyang Jiedu Huayu formula acting
on acute-on-chronic liver failure with
experimental support *in vitro* and *in vivo*.
Front. Pharmacol. 13:1105804.
doi: 10.3389/fphar.2022.1105804

COPYRIGHT
© 2022 Tang, Wang, Sun, Wu, Ding and
Mo. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Network pharmacology-based prediction of active compounds in Wenyang Jiedu Huayu formula acting on acute-on-chronic liver failure with experimental support *in vitro* and *in vivo*

Dan Tang^{1†}, Ruo-Yu Wang^{1†}, Ke-Wei Sun^{1*}, Yunan Wu¹,
Lin Ding¹ and Yang Mo²

¹Department of Hepatology, The First Hospital of Hunan University of Traditional Chinese Medicine, Changsha, China, ²Academic Affairs Office, Hunan University of Traditional Chinese Medicine, Changsha, China

KEYWORDS

acute-on-chronic liver failure, Wenyang Jiedu Huayu formula, network pharmacology, atractylenolide I, rat hepatocytes, ACLF rat model

A Corrigendum on

Network pharmacology-based prediction of active compounds in the Wenyang Jiedu Huayu formula acting on acute-on-chronic liver failure with experimental support *in vitro* and *in vivo*

by Tang D, Wang R-Y, Sun K-W, Wu Y, Ding L and Mo Y (2022). *Front. Pharmacol.* 13:1003479.
doi: 10.3389/fphar.2022.1003479

In the published article, there was an error in the **Funding statement**. The funding statement for the National Natural Science Foundation of China was displayed as “(8197152432 and 82104809).” The correct Funding statement appears below.

“Funding

This study was supported by the National Natural Science Foundation of China (81973833 and 82104809), and the Hunan University of Chinese Medicine Graduate student innovation topics (2020CX18).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.